Zuellig Pharma has acquired the Zam-Buk® and Vapex® consumer healthcare brands from Bayer Consumer Care AG, securing rights for Thailand, Singapore, Indonesia, Malaysia, and Brunei to strengthen its regional consumer healthcare portfolio.

Key Details

• Brands acquired: Zam-Buk® (pain and itch relief ointment) and Vapex® (nasal inhaler for congestion).
• Geographic scope: Rights cover Thailand, Singapore, Indonesia, Malaysia, and Brunei.
• Strategic focus: Supports Zuellig Pharma’s plan to expand its consumer healthcare platform across Asia.

This summary is based on a press release issued by Zuellig Pharma.